Medications

Review shows chloroquine doesn't help people with COVID-19

Hydroxychloroquine does not reduce deaths from COVID-19, and probably does not reduce the number of people needing mechanical ventilation, state the authors of a new Cochrane Review. In addition, they note that no new trials ...

Medications

Adverse drug reactions linked to hydroxychloroquine up in 2020

(HealthDay)—The number of adverse drug reactions (ADRs) associated with hydroxychloroquine and chloroquine more than doubled in 2020 compared with 2018 and 2019, according to a research letter published online Jan. 26 in ...

Diseases, Conditions, Syndromes

NHLBI trial concludes no benefit for hydroxychloroquine in COVID-19

(HealthDay)—Hydroxychloroquine is not beneficial for adults hospitalized with COVID-19, according to the formal conclusion of a study funded by the U.S. National Heart, Lung, and Blood Institute (NHLBI) and published online ...

page 1 from 9

Hydroxychloroquine

Hydroxychloroquine is an antimalarial drug, sold under the trade names Plaquenil,Axemal(In India), Dolquine, and Quensyl, also used to reduce inflammation in the treatment of rheumatoid arthritis (see disease-modifying antirheumatic drugs) and lupus. Hydroxychloroquine differs from chloroquine by the presence of a hydroxyl group at the end of the side chain: The N-ethyl substituent is beta-hydroxylated. It is available for oral administration as hydroxychloroquine sulfate (plaquenil) of which 200 mg contains 155 mg base in chiral form. Hydroxychloroquine has similar pharmacokinetics to chloroquine, with quick gastrointestinal absorption and is eliminated by the kidney. Cytochrome P450 enzymes (CYP 2D6, 2C8, 3A4 and 3A5) N-desethylated Hydroxychloroquine to Ndesethylhydroxychloroquine. ,

This text uses material from Wikipedia, licensed under CC BY-SA